Cargando…

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L

Hepatocyte nuclear factor 1-alpha (HNF1A) is a liver-enriched transcription factor that plays a key role in many aspects of hepatic functions including detoxification processes. We examined whether HNF1A polymorphisms are associated with clinical outcomes in two independent cohorts combining 417 Eur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labriet, Adrien, De Mattia, Elena, Cecchin, Erika, Lévesque, Éric, Jonker, Derek, Couture, Félix, Buonadonna, Angela, D’Andrea, Mario, Villeneuve, Lyne, Toffoli, Giuseppe, Guillemette, Chantal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641335/ https://www.ncbi.nlm.nih.gov/pubmed/29066969 http://dx.doi.org/10.3389/fphar.2017.00712

Ejemplares similares

Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients
por: Labriet, Adrien, et al.
Publicado: (2019)

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm
por: De Mattia, Elena, et al.
Publicado: (2021)

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: De Mattia, Elena, et al.
Publicado: (2018)

Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI
por: De Mattia, Elena, et al.
Publicado: (2019)

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer
por: Scarabel, Lucia, et al.
Publicado: (2022)

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression
por: Lévesque, Eric, et al.
Publicado: (2020)

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
por: Garziera, Marica, et al.
Publicado: (2017)

The Glycosyltransferase Pathway: An Integrated Analysis of the Cell Metabolome
por: Audet-Delage, Yannick, et al.
Publicado: (2022)

Inactivation of Prostaglandin E(2) as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia
por: Allain, Eric P., et al.
Publicado: (2019)

Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women
por: Audet-Delage, Yannick, et al.
Publicado: (2018)

Genetic biomarkers for hepatocellular cancer risk in a caucasian population
por: De Mattia, Elena, et al.
Publicado: (2017)

UGT2B17 modifies drug response in chronic lymphocytic leukaemia
por: Allain, Eric P., et al.
Publicado: (2020)

Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells
por: Bélanger, Anne-Sophie, et al.
Publicado: (2010)

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
por: De Mattia, Elena, et al.
Publicado: (2019)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
por: Bignucolo, Alessia, et al.
Publicado: (2017)

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy
por: De Mattia, Elena, et al.
Publicado: (2020)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

HLA-G 3’UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment
por: Garziera, Marica, et al.
Publicado: (2015)

A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
por: Dalle Fratte, Chiara, et al.
Publicado: (2022)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
por: De Mattia, Elena, et al.
Publicado: (2018)

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure
por: Gagno, Sara, et al.
Publicado: (2023)

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy Outcomes
por: Mezzalira, Silvia, et al.
Publicado: (2019)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Dreussi, Eva, et al.
Publicado: (2016)

Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
por: De Re, Valli, et al.
Publicado: (2014)

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients
por: Dreussi, Eva, et al.
Publicado: (2016)

Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib
por: Dalle Fratte, Chiara, et al.
Publicado: (2020)

Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis
por: De Mattia, Elena, et al.
Publicado: (2023)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

Fluorescent Imprinted Nanoparticles for the Effective Monitoring of Irinotecan in Human Plasma
por: Tommasini, Martina, et al.
Publicado: (2020)

A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome
por: Wagner, Antoine, et al.
Publicado: (2023)

Species-Specific Differences in the Expression of the HNF1A, HNF1B and HNF4A Genes
por: Harries, Lorna W., et al.
Publicado: (2009)

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

HNF1A gene p.I27L is associated with early-onset, maturity-onset diabetes of the young-like diabetes in Turkey
por: Beysel, Selvihan, et al.
Publicado: (2019)

Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
por: Bignucolo, Alessia, et al.
Publicado: (2021)

Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival
por: Nguyen Van Long, Flora, et al.
Publicado: (2023)

Identification of HNF4A Mutation p.T130I and HNF1A Mutations p.I27L and p.S487N in a Han Chinese Family with Early-Onset Maternally Inherited Type 2 Diabetes
por: Yang, Ying, et al.
Publicado: (2016)

Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression
por: Allain, Eric P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k26987polsqg5jhgfes1hgnsas